Overview

A Study to Determine the Optimal Dose and Frequency of ALDP001 Nasal Spray in Adults With Seasonal Allergic Rhinitis Under Allergen Exposure

Status:
RECRUITING
Trial end date:
2026-04-01
Target enrollment:
Participant gender:
Summary
This study aims to evaluate the effectiveness and safety of ALDP001 Nasal Spray in treating seasonal allergic rhinitis, and to identify the optimal dosage and administration frequency for this formulation.
Phase:
PHASE2
Details
Lead Sponsor:
Alixer Nexgen Therapeutics Limited